Stock analysis, AI verdict, fundamentals & technical signals
Rating: NEUTRAL
Price: $8.26 Analyst target: $37.02 Upside: 348.18%
Oculis Holding AG, a biopharmaceutical company, develops novel topical treatments for ophthalmic diseases for both back- and front-of-the-eye. The company is headquartered in Zug, Switzerland.
See the full interactive analysis & chart →Informational only — not investment advice.